2 Small-Cap Stocks With Large-Cap Potential
According to the legendary investor Peter Lynch of Fidelity fame, if investing were a baseball game, you'd want to buy stocks in the second inning of a company's lifetime, and sell them in the seventh inning -- or at least sometime before the tail end of the ninth, when everyone in the stadium is usually standing up and walking out.
For many purposes, that bit of wisdom often means buying shares in businesses with a market cap of less than $2 billion that have the chance of growing to be worth upward of $10 billion after experiencing a few reasonable catalysts. There are a plethora of companies that could fit the bill, so let's look at a pair of contenders in biotech to start.
With a market cap of just over $1 billion, Veru (NASDAQ: VERU) is a biotech with a lot of potential growth ahead. Its lead candidate is an antiviral and anti-inflammatory drug called sabizabulin, which is being investigated in treating severe COVID-19 as well as certain breast cancers and treatment-resistant prostate cancer in a handful of late-stage clinical trials.
Source Fool.com
